- Home
- MMU vs EVMN Comparison
MMU vs EVMN Comparison
Compare MMU & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMU | EVMN |
|---|---|---|
| Founded | 1992 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 474.7M |
| IPO Year | 1994 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MMU | EVMN |
|---|---|---|
| Price | $8.90 | $7.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.13 |
| AVG Volume (30 Days) | 223.4K | ★ 692.3K |
| Earning Date | 01-01-0001 | 11-07-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $40.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $8.71 | $8.11 |
| 52 Week High | $10.71 | $33.20 |
Technical Indicators
Market Signals| Indicator | MMU | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 22.38 | 24.88 |
| Support Level | N/A | N/A |
| Resistance Level | $10.59 | $13.35 |
| Average True Range (ATR) | 0.13 | 0.47 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 21.28 | 2.78 |
Price Performance
Historical ComparisonAbout MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.